BACKGROUND: Human papillomavirus (HPV) infection is considered a necessary step for the development of cervical cancer, and >95% of all cervical cancers have detectable HPV sequences. The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer. They hypothesized that the pretreatment of tumor cells with various agents that cause cell death and/or elevation of E6 levels would increase the accumulation of radiolabeled antibodies to E6 in cervical tumors. METHODS: HPV type 16 (HPV-16)-positive CasKi cells were treated in vitro with up to 6 grays of external radiation, or with the proteasome inhibitor MG-132, or with unlabeled anti-E6 antibody C1P5; and cell death was assessed. The biodistribution of (188)Re-labeled C1P5 antibody was determined in both control and radiation MG-132-treated CasKi tumor-bearing nude mice. RESULTS: (188)Re-C1P5 antibody demonstrated tumor specificity, very low uptake, and fast clearance from the major organs. The amount of tumor uptake was enhanced by MG-132 but was unaffected by pretreatment with radiation. In addition, in vitro studies demonstrated an unanticipated effect of unlabeled antibody on the amount of cell death, a finding that was suggested by the authors' previous in vivo studies in a CasKi tumor model. CONCLUSIONS: The current results indicated that pretreatment of cervical tumors with the proteasome inhibitor MG-132 and with unlabeled antibody to E6 can serve as a means to generate nonviable cancer cells and to elevate the levels of target oncoproteins in the cells for increasing the accumulation of targeted radiolabeled antibodies in tumors. These results favor the further development of RIT for cervical cancers targeting viral antigens. (c) 2010 American Cancer Society.
BACKGROUND:Humanpapillomavirus (HPV) infection is considered a necessary step for the development of cervical cancer, and >95% of all cervical cancers have detectable HPV sequences. The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer. They hypothesized that the pretreatment of tumor cells with various agents that cause cell death and/or elevation of E6 levels would increase the accumulation of radiolabeled antibodies to E6 in cervical tumors. METHODS:HPV type 16 (HPV-16)-positive CasKi cells were treated in vitro with up to 6 grays of external radiation, or with the proteasome inhibitor MG-132, or with unlabeled anti-E6 antibody C1P5; and cell death was assessed. The biodistribution of (188)Re-labeled C1P5 antibody was determined in both control and radiation MG-132-treated CasKitumor-bearing nude mice. RESULTS: (188)Re-C1P5 antibody demonstrated tumor specificity, very low uptake, and fast clearance from the major organs. The amount of tumor uptake was enhanced by MG-132 but was unaffected by pretreatment with radiation. In addition, in vitro studies demonstrated an unanticipated effect of unlabeled antibody on the amount of cell death, a finding that was suggested by the authors' previous in vivo studies in a CasKitumor model. CONCLUSIONS: The current results indicated that pretreatment of cervical tumors with the proteasome inhibitor MG-132 and with unlabeled antibody to E6 can serve as a means to generate nonviable cancer cells and to elevate the levels of target oncoproteins in the cells for increasing the accumulation of targeted radiolabeled antibodies in tumors. These results favor the further development of RIT for cervical cancers targeting viral antigens. (c) 2010 American Cancer Society.
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Ekaterina Revskaya; Artemio M Jongco; Rani S Sellers; Robertha C Howell; Wade Koba; Allan J Guimaraes; Joshua D Nosanchuk; Arturo Casadevall; Ekaterina Dadachova Journal: Clin Cancer Res Date: 2009-03-17 Impact factor: 12.531
Authors: Jian Yan; Dawn K Reichenbach; Natasha Corbitt; David A Hokey; Mathura P Ramanathan; Kibwei A McKinney; David B Weiner; Duane Sewell Journal: Vaccine Date: 2008-11-18 Impact factor: 3.641
Authors: Xing Guo Wang; Ekaterina Revskaya; Ruth A Bryan; Howard D Strickler; Robert D Burk; Arturo Casadevall; Ekaterina Dadachova Journal: PLoS One Date: 2007-10-31 Impact factor: 3.240
Authors: Christian R Salazar; Richard V Smith; Madhur K Garg; Missak Haigentz; Bradley A Schiff; Nicole Kawachi; Nicole Anayannis; Thomas J Belbin; Michael B Prystowsky; Robert D Burk; Nicolas F Schlecht Journal: Head Neck Pathol Date: 2013-09-04
Authors: Rébécca Phaeton; Matthew Harris; Zewei Jiang; Xing Guo Wang; Mark H Einstein; Gary L Goldberg; Arturo Casadevall; Ekaterina Dadachova Journal: Cancer Biol Ther Date: 2010-11-15 Impact factor: 4.742
Authors: R Phaëton; J Gutierrez; Z Jiang; R G Karabakhtsian; J Albanese; J Sunkara; D R Fisher; G L Goldberg; E Dadachova Journal: Immunotherapy Date: 2015-06-22 Impact factor: 4.196
Authors: Julie K Jang; Leslie A Khawli; Ryan Park; Brian W Wu; Zibo Li; David Canter; Peter S Conti; Alan L Epstein Journal: Mol Cancer Ther Date: 2013-10-15 Impact factor: 6.261
Authors: Rebecca Phaeton; Zewei Jiang; Ekaterina Revskaya; Darrell R Fisher; Gary L Goldberg; Ekaterina Dadachova Journal: Cancer Med Date: 2015-12-02 Impact factor: 4.452
Authors: M Harris; X G Wang; Z Jiang; R Phaeton; W Koba; G L Goldberg; A Casadevall; E Dadachova Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640